Companies in the News

Gritstone Oncology and Arbutus Biopharma Announce LNP Technology Licensing Agreement to Develop Nove

VANCOUVER, British Columbia and WARMINSTER, Pa. and EMERYVILLE, Calif., Oct. 18, 2017 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq:ABUS), an industry-leading hepatitis B virus (HBV) therapeutic solutions company, and Gritstone Oncology, a leader in personalized cancer immunotherapies, today announced a collaboration and license agreement. Arbutus is deploying its proprietary lipid nanoparticle (LNP) technology to deliver Gritstone's RNA-based neoantigen immunotherapy products. Under the terms of this license agreement, Gritstone obtains worldwide access to Arbutus' portfolio of proprietary and clinically validated LNP products and associated intellectual property. Gritstone will

Vir Biotechnology Builds Pipeline, Capabilities, and Lays Out Strategy to Address Serious Infectious

-- Expands technology and global footprint with acquisition of Humabs BioMed SA -- Accesses clinical and preclinical stage assets from Alnylam, Visterra -- Total financing to date exceeds $500 million SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. today announced agreements with Humabs BioMed SA, Alnylam Pharmaceuticals, Inc. (NASDAQ:ALYN), and Visterra, Inc., as well as four leading academic research institutions. Together with the company’s internal research and development capabilities, these achievements provide the foundation on which Vir will pursue its mission of transforming the care of people with serious infectious diseases. To support these efforts, Vir has secured financ

eFFECTOR Therapeutics Initiates Dosing in Phase 2 Combination Trial of EFT508 and Avelumab in Micros

Study conducted in collaboration with Merck KGaA, Darmstadt, Germany, and Pfizer SAN DIEGO, October 4, 2017 – eFFECTOR Therapeutics, Inc., a leader in the development of selective translation regulators (STRs) for the treatment of cancer, today announced it has initiated dosing in a Phase 2 clinical study of eFT508 in combination with avelumab* in microsatellite stable colorectal cancer (MSS CRC). The trial (NCT03258398) is being conducted under a clinical collaboration and supply agreement announced earlier this year between eFFECTOR and a global strategic alliance of Pfizer and Merck, KGaA, Darmstadt, Germany. “eFT508 promotes anti-tumor immune response and we believe it has the potential